WHO ICTRP trial
Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention…
JPRN-jRCTs041200063 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs041200063 |
|---|---|
| Public title | Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16) |
| Scientific title | Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16) |
| Primary sponsor | Toshihiro Miyamoto |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | AML with t(8;21)(q22;q22);RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22);CBFB-MYH11 AML, t(8;21)(q22;q22);RUNX1-RUNX1T1, inv(16)(p13.1q22)/t(16;16)(p13.1;q22);CBFB-MYH11 |
| Interventions | After remission indcution treatment, CBF-AML patients reaching a complete remission (CR) who have obtained more than 3-log MRD reduction undergo high-dose of cytarabine (HiDAC) for 3 cycles, while patients who have gained less than 3-log… |
| Registration date | Nov 13, 2020 |
| Target size | 117 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: